$ACB Analyst typical double speak . “Cost cutting or asset sales could help cash position,” Lavery noted. “We project lower capex, falling costs and improving margins, but Aurora could take more significant austerity measures than we model.” Carey wrote that with cash tight, uncertainty about the outlook will likely carry into the second half of 2020. “TO BE CLEAR, we expect the covenants to be restructured, a big step in helping investor confidence,” he wrote, referring to the terms of the C$400 million credit facility. “Once this and visibility on financial delivery improves (and valuation with it), we see an opportunity to return focus to ACB’s key positive qualities.” The stock has lost 75% since April and now they are concerned? None of these issues are "unknowns" and priced in < $2. The drop was a yawn with only $.06 from the recent low of $1.71! Compared to a cash burning $5 biotech with the "hope" of an FDA approval some day ACB is in 25 countries with real revenue.
  • 4
  • 3